Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 20Prostatic Neoplasms 19Glioblastoma 18Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 12Rectal Neoplasms 11Oropharyngeal Neoplasms 10Neoplasms 9Head and Neck Neoplasms 8Glioma 8Astrocytoma 8Neoplasm Metastasis 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Squamous Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Hodgkin Disease 5Gliosarcoma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Burkitt Lymphoma 5Brain Neoplasms 5Adenocarcinoma of Lung 5Adenocarcinoma Of Esophagus 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Etoposide 30Carboplatin 29atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11Specimen Handling 9PM 01183 9Magnetic Resonance Spectroscopy 7pembrolizumab 6olaparib 5berzosertib 4anlotinib 4Radiotherapy 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Paclitaxel 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2cabozantinib 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Radiotherapy × 90 days × Clear all
NCT05092412 2026-05-08

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Sichuan University

Phase 2 Active not recruiting
30 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05765825 2026-04-29

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Sichuan University

Phase 2 Active not recruiting
61 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06732258 2026-04-29

Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Sichuan University

Phase 1 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡